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Abstract
Introduction: Fibrinogen plays a key role in hemostasis and is the first coagulation factor to reach critical levels in
massively bleeding trauma patients. Consequently, rapid estimation of plasma fibrinogen (FIB) is essential upon
emergency room (ER) admission, but is not part of routine coagulation monitoring in many centers. We
investigated the predictive ability of the laboratory parameters hemoglobin (Hb) and base excess (BE) upon
admission, as well as the Injury Severity Score (ISS), to estimate FIB in major trauma patients.
Methods: In this retrospective study, major trauma patients (ISS ≥16) with documented FIB analysis upon ER
admission were eligible for inclusion. FIB was correlated with Hb, BE and ISS, alone and in combination, using
regression analysis.
Results: A total of 675 patients were enrolled (median ISS 27). FIB upon admission correlated strongly with Hb,
BE and ISS. Multiple regression analysis showed that Hb and BE together predicted FIB (adjusted R2 = 0.46;
loge(FIB) = 3.567 + 0.223.Hb - 0.007.Hb
2 + 0.044.BE), and predictive strength increased when ISS was included
(adjusted R2 = 0.51; loge(FIB) = 4.188 + 0.243.Hb - 0.008.Hb
2 + 0.036.BE - 0.031.ISS + 0.0003.ISS2). Of all major
trauma patients admitted with Hb <12 g/dL, 74% had low (<200 mg/dL) FIB and 54% had critical (<150 mg/dL)
FIB. Of patients admitted with Hb <10 g/dL, 89% had low FIB and 73% had critical FIB. These values increased to
93% and 89%, respectively, among patients with an admission Hb <8 g/dL. Sixty-six percent of patients with only a
weakly negative BE (<−2 mmol/L) showed low FIB. Of patients with BE <−6 mmol/L upon admission, 81% had low
FIB and 63% had critical FIB. The corresponding values for BE <−10 mmol/L were 89% and 78%, respectively.
Conclusions: Upon ER admission, FIB of major trauma patients shows strong correlation with rapidly obtainable,
routine laboratory parameters such as Hb and BE. These two parameters might provide an insightful and rapid tool
to identify major trauma patients at risk of acquired hypofibrinogenemia. Early calculation of ISS could further
increase the ability to predict FIB in these patients. We propose that FIB can be estimated during the initial phase
of trauma care based on bedside tests.
Introduction
Trauma-induced coagulopathy (TIC) has been reported
in 25 to 35% of all injured patients upon admission to the
emergency room (ER) [1,2]. Established TIC strongly
increases the risk of massive transfusion (MT), prolonged
length of intensive care unit (ICU) and hospital stay, and
mortality [1]. Importantly, coagulation factors do not
decrease in a uniform manner in severely bleeding
patients. Plasma fibrinogen (FIB) reaches critically low
levels earlier than any other coagulation factor [3] and
low FIB is almost always the primary coagulation factor
deficiency during major bleeding, as shown for example
in trauma [4] and postpartum hemorrhage (PPH) [5].
Fibrinogen plays a central role in primary and secondary
hemostasis [6]. It has a high affinity for glycoprotein IIb/
IIIa receptors which are expressed on activated platelets
and is therefore essential for platelet aggregation. More-
over, fibrinogen is a substrate of the coagulation process
and precursor of the fibrin network. Low FIB has been
associated with increased blood loss and/or transfusion
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requirements in a number of settings, including cardiac
surgery, PPH and trauma [7-11], and has recently been
reported to worsen outcomes in trauma patients receiving
MT [12]. Thus, early replacement of fibrinogen is bene-
ficial in trauma patients experiencing severe bleeding
[13-18], and the recent European trauma guidelines
recommend a FIB threshold concentration for bleeding
patients of 150 to 200 mg/dL as a trigger for replacement
therapy [19].
In the AUVA Trauma Centre of Salzburg, rapid point-of-
care (POC) estimation of fibrin polymerization (that is via
the FIBTEM assay on thromboelastometry (ROTEM)) has
been established to diagnose fibrinogen deficiencies and to
guide fibrinogen substitution in major trauma patients
[10,14,15,20-22]. POC blood gas analyses and full blood
cell counts are routinely performed in severe trauma
patients upon admission to the ER. Furthermore, standard
laboratory tests including prothrombin time (PT), activated
partial thromboplastin time (aPTT) and FIB, are performed
in the hospital’s central laboratory with the highest priority.
A major problem with these tests is the long turnaround
time: the average time for results to reach the clinician is
typically around 45 minutes and longer durations have
been published [23,24]. Furthermore, PT and aPTT were
principally designed for monitoring warfarin and heparin.
For these reasons, coagulation management in our insti-
tution is based mainly on the results of POC tests, parti-
cularly ROTEM analysis (thrombelastography (TEG)
could be a viable alternative to ROTEM). However, in
many trauma centers, neither ROTEM nor TEG is routi-
nely used for assessing trauma patients, and it is also
common for FIB to be missing from routine coagulation
assessment.
We therefore conducted a retrospective study to investi-
gate the predictive ability of the laboratory parameters
hemoglobin (Hb) and base excess (BE) to estimate FIB of
major trauma patients upon admission to the ER. To
increase the accuracy of these predictions, we included the
Injury Severity Score (ISS) in the analyses.
Material and methods
The ethics committee of the federal state of Salzburg
(Ehtikkommission für das Bundesland Salzburg)
approved (Protocol: 415-EP/73/197-2013) this retrospective
analysis of data from all major trauma patients (ISS ≥16)
admitted to the ER of the AUVA Trauma Centre, Salzburg,
Austria, between January 2005 and December 2012 and
waived the need for patients’ informed consent.
The laboratory parameters of interest in this study, Hb
(g/dL), BE (mmol/L) and FIB (mg/dL, Clauss method)
were documented with the time of admission in the
electronic patient database of the hospital or the patient
charts. We considered the main parameters for quick
estimation of FIB in this study to be Hb and BE. However,
for the addition of a measure of injury severity, we also
aimed to include ISS.
ISS, hospital mortality, sex and age were documented
in the electronic ICU documentation (ICdoc) or, in
cases where the patient was not admitted to the ICU, in
the electronic patient database of the hospital. ISS was
calculated according to the final diagnosis of all detected
patient injuries at the end of stay.
Statistical analysis
Continuous study variables (FIB, Hb, BE, ISS and age)
were analyzed for normal distribution by the Kolmogorov-
Smirnov test. To detect differences between groups, either
the Student’s t test or the Mann-Whitney U test was
performed, depending on the underlying distribution.
Categorical variables were analyzed with Fisher’s exact
test. Overall group differences were compared by the
Kruskal-Wallis or the chi-square test. A Spearman correla-
tion analysis was performed to correlate Hb, BE and ISS
with FIB. Unless otherwise stated, data are presented as
median (interquartile range (IQR)) for continuous variables,
and as number (percentages) for categorical variables. Over-
all, a P value <0.05 was considered significant for all statisti-
cal tests. Standard statistical calculations were performed
using GraphPad Prism 5 (GraphPad Software, La Jolla,
CA, USA).
A multivariate analysis was carried out to examine the
ability of the parameters Hb, BE and ISS to predict FIB.
Linear regression was used to examine the relationship
between all three parameters and FIB. Due to the slightly
positively skewed distribution and issues of homoscedasti-
city, the regression analyses were performed with FIB on
the log scale. Initially, the effect of each predictor variable
upon FIB was examined separately, and the nature of the
relationship between each predictor and the outcome was
examined. If the relationship was found to be nonlinear,
then squared terms for each predictor were introduced.
Subsequently, the effect of each of the predictor variables
was evaluated in combination using predetermined combi-
nations of variables. The predictive ability of the models
was assessed by the R2 and adjusted R2 statistics. Multi-
variate statistical calculations were performed using the
statistical software package Stata 12.1 (StatCorp LP,
College Station, TX, USA).
Results
A total of 680 major trauma patients with documented
FIB analysis immediately after admission were identified.
Of these, 675 were eligible for inclusion (three patients
were excluded due to participation in another study, and
a further two patients were excluded for nontrauma-
related admission). ISS and Hb values were available for
all 675 patients, BE for 576 patients only.
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Median ISS was 27 (20 to 38 IQR), median age was 45
(27 to 59 IQR) and 537 (79.6%) patients were male.
Overall in-hospital mortality of the study cohort was
15.7% (n = 106). Patient characteristics were stratified
according to ISS (Table 1).
Correlation and multiple regression analysis
When examined individually, all three variables (Hb, BE
and ISS) were strongly associated with FIB (Figure 1A
to 1C). We then examined the separate effect of each of
the three predictor variables upon FIB. The results of
these analyses are summarized in Table 2. The strongest
predictor was Hb (R2 = 0.40), followed by BE (R2 = 0.29);
these parameters explained the largest proportion of the
variation in fibrinogen values. The relationship between
FIB and the predictor variables Hb and ISS were found to
be nonlinear.
Subsequently, various combinations of variables were
analyzed together in a series of multiple regression ana-
lyses. The results of these analyses are summarized in
Table 3. Even after adjusting for the effects of the other
variables each of the three variables remained statistically
significant, suggesting that all three are independent
predictors of FIB.
By analyzing different combinations of the three vari-
ables, the following models for the prediction of FIB were
generated:
Model 1 (Hb, BE) loge(FIB) = 3.567 + 0.223.Hb -
0.007.Hb2 + 0.044.BE
Model 2 (BE, ISS) loge(FIB) = 6.129 + 0.056.BE -
0.034.ISS + 0.0003.ISS2
Model 3 (Hb, ISS) loge(FIB) = 3.609 + 0.301.Hb -
0.009.Hb2 - 0.029.ISS + 0.0002.ISS2
Model 4 (Hb, BE, ISS) loge(FIB) = 4.188 + 0.243.Hb -
0.008.Hb2 + 0.036.BE - 0.031.ISS + 0.0003.ISS2
Model 1, including the two main variables to quickly
calculate FIB, provides an adjusted R2 value of 0.46, sug-
gesting that 46% of the variation in fibrinogen values
can be explained by the combination of Hb and BE
(Table 3). The model containing all three variables
(Model 4) provides the highest predictive ability. The
adjusted R2 value from this model was 0.51, suggesting
that 51% of the variation in fibrinogen values can be
explained by the combination of three predictor
variables.
Clinical applicability
Overall, 74% of major trauma patients admitted with
Hb <12 g/dL had low (<200 mg/dL) FIB, and critical
(<150 mg/dL) FIB was observed in 54%. Of patients
admitted with Hb <10 g/dL, 89% had low FIB and 73%
had critical FIB. These values increased to 93% and
89%, respectively, among patients with an admission
Hb <8 g/dL. Sixty-six percent of patients with only a
weakly negative BE (<−2 mmol/L) showed low FIB. Of
patients with BE <-6 mmol/L upon admission, 81%
had low FIB and 63% had critical FIB. Changing the
criterion to an admission BE <-10 mmol/L produced a
low FIB rate of 89% and a critical FIB rate of 78%.
Considering the ISS, 56% of major trauma patients
with a score ≥16 showed low FIB. The corresponding
percentages among patients with ISS ≥25, ≥35 and ≥50
were 68%, 88% and 93%, respectively. Critically low
FIB was observed in 67% of patients with ISS ≥35 and
in 74% of those with ISS ≥50.
Based on results from the above evaluation, we
designed charts to rapidly, easily and accurately identify
those patients at risk of low (<200 mg/dL) and critical
(<150 mg/dL) FIB levels.
For each of the three variables patients were arranged
into the following categories:
Hb (g/dL) <8.0; 8.0 to 9.9; 10.0 to 11.9; ≥12.0
BE (mmol/L) <−10; −10.0 to −6.1; −6.0 to −2.1; ≥−2.0
ISS 16 to 24; 25 to 34; 35 to 49; 50 to 75
FIB was found to significantly change according to
each category (Figure 2A to 2C).
Table 1 Patient demographics stratified according to Injury Severity Score.
ISS 16-24 ISS 25-34 ISS 35-49 ISS 50-75 P value for all 4 group
differences
Patients n (% of total) 242 (35.9%) 249 (36.9%) 97 (14.4%) 87 (12.9%) N/A
Age (range) 42.5 (26-56) 47 (29.5-60)ns 45 (24-59)ns 42 (25-59)ns nsKruskal- Wallis
Male n (% of ISS group) 200 (82.6%) 195 (78.3%)ns 76 (78.4%)ns 66 (75.9%)ns nsChi-square
Mortality n (% of ISS
group)
5 (2.1%) 32 (12.9%)*** 27 (27.8%)** 42 (48.3%)** ***Chi-square
FIB mg/dL (IQR) 235 (182.5-286.3) 191.0 (143-240)*** 134 (94.5-185.5)*** 114 (69-156)* ***Kruskal- Wallis
Hb g/dL (IQR) 13.0 (11.7-14.2) 12.3 (10.6-13.7)*** 10.9 (8.4-13.0)*** 9.6 (7.0-11.6)** ***Kruskal- Wallis
BE mmol/L (IQR) −2.6 (−4.5 to
−1.4)
−3.7 (−6.2 to −2.1)
***
−5.7 (−8.5 to −2.9)
***
−7.1 (−10.9 to −4.6)
**
***Kruskal- Wallis
ns, not significant, *P <0.05, **P <0.01, ***P <0.001, significance values for comparison with previous group. BE, base excess; FIB, plasma fibrinogen; Hb,
hemoglobin; IQR, interquartile range; ISS, Injury Severity Score.
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We then combined two variables together at a time
and calculated the resulting median FIB level for each
new group (Figure 3). In this way, we were able to easily
identify patients at risk of low or critical FIB, when
combining the rapidly obtainable, routine laboratory
parameters Hb and BE upon admission (Figure 3A).
Combining ISS with either Hb or BE can be used in the
same way (Figures 3B and 3C). In each category, the
observed percentage of patients with adequate FIB
(≥200 mg/dL, green), low FIB (199 to 150 mg/dL,
orange) and critical FIB (<150 mg/dL, red) was identified
and is shown in Figures 4 to 6.
Discussion
In the current study, we found that FIB concentration
upon admission to the ER is strongly correlated with
the severity of injury, blood loss, dilution and shock.
The statistical analysis suggests that Hb, BE and ISS,
either alone or in combination, allow estimation of FIB
in major trauma patients upon admission. Together,
these three parameters account for approximately 51%
of the variability in the observed fibrinogen concentration
values. Furthermore, Hb and BE in combination (and
alternatively/additionally ISS) could be used to rapidly
identify major trauma patients at risk of low (<200 mg/dL)
and critical (<150 mg/dL) FIB concentration.
The most striking finding of the current study is that
51% of the variability in FIB can be explained by Hb, BE
and ISS. Shock and substantial tissue injury have been
identified as important drivers of TIC, resulting in a profi-
brinolytic state via the activation of the protein C pathway
[1,19,25,26]. Our findings are a proof of the concept that
TIC (considered to be a distinct, multifactorial, primary
disorder, secondarily amplified by consumption, loss and
dilution) requires two conditions: hemodynamic instability
(that is shock) and sufficiently massive tissue damage.
Therefore, besides blood loss and dilution, both tissue
trauma and hypoperfusion independently decrease FIB
concentration.
Fibrinogen is an important coagulation factor, acting
not only as the precursor of fibrin, the end product of
the coagulation process [6,27], but also as a key ligand
between activated platelets [28]. In several clinical studies
in cardiac surgery and PPH, fibrinogen deficiency was
associated with increased blood loss and transfusion
requirements [7-9]. For trauma patients, low fibrinogen
on admission to the ER was associated with increased
transfusion requirements and mortality [10,11]. These
data have been confirmed recently by further analyses of
the PROMMTT study [29].
There are many reasons for decreased FIB concentra-
tion, including easily detectable variables such as blood
loss, dilution, hypothermia and acidosis, and harder to
detect variables such as consumption, hyperfibrinolysis
and measurement-specific variability. In severe bleeding
during elective surgery, FIB reaches critically low levels
earlier than any other coagulation protein [3]. In light of
the threshold levels used by Hiippala et al. (100 mg/dL), it
may be speculated that current recommended thresholds
Figure 1 Correlation between FIB and Hb, BE or ISS. Plasma
fibrinogen concentration (FIB, mg/dL) versus (A) hemoglobin (Hb,
g/dL), (B) base excess (BE, mmol/L) and (C) Injury Severity Score
(ISS). The fitted regression line (solid) is shown along with a
corresponding 95% confidence interval (dotted lines).
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levels (150 to 200 mg/dL) could be reached with a smaller
volume of blood loss.
Rourke et al. showed that increasing shock severity was
associated with a drop in FIB (n = 517) [16]. The same
group recently found in a study of 300 patients that TIC,
as defined by a calculated prothrombin time ratio >1.2, is
associated with a low mean FIB of 96 mg/dL, as compared
to 220 mg/dL in noncoagulopathic patients [30]. This
suggests that PT is a predictor of coagulopathy caused by
low fibrinogen. Floccard et al. also reported that in blood
samples drawn immediately upon admission from trauma
patients with ISS >40, median FIB concentration was 120
mg/dL [31]. Dilutional coagulopathy was unlikely, as
patients did not receive significant amounts of fluid prior
to blood collection; therefore, low observed FIB levels
could be due to profibrinolytic breakdown and/or con-
sumption. These results are in agreement with those from
a study by Tauber et al. of coagulation factor levels in
334 trauma patients on admission to the ER, in which FIB
concentration was significantly reduced (median 160 mg/
dL) in patients with ISS >50 [11]. This is similar to our
results, where we observed a median FIB of 114 mg/dL for
all patients with ISS >50, and higher median FIB concen-
trations in patient groups with ISS 35 to 49 (median
134 mg/dL), ISS 25 to 34 (median 191 mg/dL) and ISS
16 to 24 (median 235 mg/dL) (Table 1).
Fluid therapy plays an essential role in restoring intra-
vascular volume in massive hemorrhage. The main side
effect of volume resuscitation using crystalloids is dilu-
tional coagulopathy. Additionally, artificial colloids, such
as starches and gelatins, impair fibrin polymerization
[32]. Data from 8,724 patients from the German trauma
registry revealed that early traumatic coagulopathy was
associated with the amount of intravenous fluids admi-
nistered preclinically [2]. Floccard et al., who studied
FIB levels at the trauma scene and in the ER, observed a
decrease in median FIB from 260 to 210 mg/dL in
patients receiving median 500 mL of prehospital fluid
[31]. In more severely injured patients (ISS >40) receiv-
ing 1,250 mL of prehospital fluid, a FIB of 120 mg/dL
was measured. The fall in FIB levels observed between
the trauma scene and admission to the ER may be
explained in part by the administration of intravenous
fluids. The impact of blood loss and subsequent dilution
due to prehospital fluid administration can be detected
in our study, as Hb is directly proportional to FIB
(Table 2; Figure 1A); this may explain up to 40% of the
variation in FIB observed in the studied patients.
In the current study, we have shown that more negative
BE values are associated with lower FIB levels. Although
current experimental models of acidosis are insufficient
to explain trauma and shock-induced acidosis, Martini et
al. showed that, in a pig model, HCl-induced acidosis
resulted in premature degradation of fibrinogen [33].
Furthermore, White et al. observed reduced fibrinogen
with increasing severity of shock [34]. This suggests a
possible cause for the low FIB values in patients with
more negative BE values in this study.
Increased consumption of coagulation factors at the
site of injury may contribute to lower FIB levels in
trauma patients. In patients with severe traumatic brain
Table 2 Effect of hemoglobin, base excess and Injury
Severity Score upon plasma fibrinogen.
Variable Term Ratio (95% CI) P value R2 Adj. R2
Hb* Linear term 4.96 (3.47, 7.11) <0.001 0.40 0.40
Squared term 0.80 (0.73, 0.86)
BE* Linear term 1.44 (1.38, 1.51) <0.001 0.29 0.29
ISS** Linear term 0.70 (0.62, 0.79) <0.001 0.26 0.25
Squared term 1.02 (1.00, 1.03)
*Ratios reported for a 5-unit increase in predictor variable; **ratios reported
for a 10-unit increase in predictor variable. Adj., adjusted; BE, base excess; Hb,
hemoglobin; ISS, Injury Severity Score.
Table 3 Multiple regression models showing the
combined effect of hemoglobin, base excess and Injury
Severity Score upon plasma fibrinogen.
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BE* Linear term 1.20 (1.14,
1.25)
<0.001







*Ratios reported for a 5-unit increase in predictor variable; **ratios reported
for a 10-unit increase in predictor variable. Adj., adjusted; BE, base excess; CI,
confidence interval; Hb, hemoglobin; ISS, Injury Severity Score.
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injury there is an increased risk of disseminated intra-
vascular coagulation (DIC) [21], which would further
increase the consumption of coagulation factors.
Furthermore, hyperfibrinolysis (HF) is common in
trauma and this can lead to very low FIB values. Schöchl
Figure 2 FIB stratified according to different categories of Hb,
BE and ISS. Plasma fibrinogen concentration (FIB, mg/dL) stratified
according to (A) hemoglobin (Hb, g/dL), (B) base excess (BE, mmol/
L) and (C) Injury Severity Score (ISS).***P <0.001. Boxes indicate the
range between the 25th and 75th percentile, whiskers represent the
range between the 5th and 95th percentile, horizontal lines
represents the median, and black circles represent outliers. Yellow
areas represents FIB values between 199 and 150 mg/dL, red areas
indicates FIB values below 150 mg/dL.
Figure 3 Combined admission variables resulting in a median
plasma fibrinogen level (FIB, mg/dL). (A) Hemoglobin (Hb, g/dL)
and base excess (BE, mmol/L), (B) Injury Severity Score (ISS) and Hb,
and (C) ISS and BE. Green columns indicate adequate FIB (≥200
mg/dL), yellow columns indicate low FIB (<200 mg/dL), and red
columns indicate critical FIB (<150 mg/dL).
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et al. observed FIB levels of 80 ± 40 mg/dL in 33
trauma patients with established HF diagnosed with
ROTEM [20]. Cotton et al. reported a median FIB value
of 55 (52 to 219 IQR) mg/dL in 41 patients with HF, as
diagnosed by TEG [35]. Despite resulting in low FIB
values, HF cannot be detected directly by standard
laboratory parameters alone [36]. In our current study,
HF could have led to some extreme outliers with very
low FIB values, even in patient groups not usually at
risk of critical FIB levels (Figure 2).
When comparing FIB across different studies, it has to
be taken into account that there are more than 60 differ-
ent ways of measuring fibrinogen concentration, including
numerous variations of the von Clauss method [37]. This
introduces many factors that may affect the measured
FIB, including the type of device, software, readout
method, activators or calibration. Furthermore, it has been
observed that the presence of artificial colloids (for
example dextran or hydroxyethyl starch (HES)) signifi-
cantly raises FIB measured using the PT-derived and von
Clauss methods to levels above those predicted by the
dilutional effect [38]. Thus, when high volumes of syn-
thetic colloids are used during MT, hypofibrinogenemia
may potentially be overlooked. This possibility has been
confirmed by Adam et al., who reported that photo-optical
methods significantly overestimate FIB in blood diluted
with HES [39]. These studies showed that FIB was over-
estimated by >50% and >100% with 30% and 50% dilution,
respectively. Notably, in this context the concentration
of HES appears to be more important than molecular
size [39,40].
Data showing that fibrinogen supplementation improves
survival in trauma patients are limited. However, experi-
mental and initial clinical studies have reported promising
outcomes following replacement of fibrinogen as the initial
step in managing TIC [13,15,41,42]. Stinger et al. were the
Figure 4 Percentage of patients with adequate, low and critical FIB stratified according to Hb and BE. Observed percentage of patients
with adequate plasma fibrinogen concentration (FIB) (≥200 mg/dL, green), low FIB (199 to 150 mg/dL, yellow) and critical FIB (<150 mg/dL, red)
when combining the admission variables hemoglobin (Hb, g/dL) and base excess (BE, mmol/L).
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first to show that a high ratio of red blood cells (RBCs)
and fibrinogen resulted in improved outcomes [13]. Cur-
rently there are three potential sources of fibrinogen repla-
cement therapy: therapeutic plasma (such as fresh frozen
plasma (FFP)), cryoprecipitate and fibrinogen concentrate
(FC). When using FFP, high-volume transfusion is neces-
sary to provide sufficient increase in FIB. Larger and more
rapid increases can be achieved using either cryopreci-
pitate or FC. However, cryoprecipitate contains variable
quantities of fibrinogen, it must be thawed before use,
and there have been significant safety concerns regarding
the use of this product, mainly relating to a lack of viral
inactivation. In contrast, FC is rapidly available, contains a
high and standardized amount of fibrinogen, and is virally
inactivated. In most European countries, cryoprecipitate is
no longer used, and instead FC is available, delivering con-
sistent amounts of fibrinogen [43]. Currently, a rando-
mized pilot study in trauma patients is exploring the use
of FC in the prehospital area [44].
The main limitation of the present study is its retro-
spective, uncontrolled nature. For example, we were not
able to identify co-medications or comorbidities that
could have influenced test results. Furthermore, we did
not document hypothermia, which has been shown to
influence fibrinogen synthesis in the liver [33]. However,
this seems to be of greater importance for a longer
observation period rather than upon ER admission. We
also did not document preclinical fluid therapy, which
might significantly influence TIC [2] and therefore FIB
upon admission. However, we speculate that the admis-
sion parameter Hb indirectly includes the influence of
preclinical fluid therapy on FIB levels. The multiple
regression model of Hb, BE and ISS explains around
51% of the variation observed in admission FIB. While
the remaining variation is still unexplained by these
variables, estimation of FIB through Hb, BE and ISS
seems acceptable and inclusion of further variables is
unlikely to substantially improve prediction. A high
Figure 5 Percentage of patients with adequate, low and critical FIB stratified according to ISS and BE. Observed percentage of patients
with adequate plasma fibrinogen concentration (FIB) (≥200 mg/dL, green), low FIB (199 to 150 mg/dL, yellow) and critical FIB (<150 mg/dL, red)
when combining the admission variables Injury Severity Score (ISS) and base excess (BE, mmol/L).
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percentage of variation may arise from the normal phy-
siological variation seen in human FIB values (200 to
450 mg/dL) [10]. Patients with high normal baseline FIB
values will tolerate much higher blood loss and dilution
before FIB falls to critical levels, as compared to patients
in the lower range of normal baseline values, in whom
even a little hemodilution may induce dilutional coagulo-
pathy [45]. Another consideration is that ISS is normally
calculated at the end of stay, limiting the possibility of
using this parameter for an early estimate of FIB. However,
the ISS was developed in 1974 when trauma scans were
not universally available [46]. Nowadays, practically all
trauma centers in industrialized countries are equipped
with computed tomography (CT) scanners, enabling
important injuries to be diagnosed within a couple of min-
utes. Thus, an early estimation of ISS could conceivably be
used for estimating FIB. Finally, we only included patients
with blunt trauma. Therefore, the results of the current
study provide FIB estimation for blunt injury only and will
need to be confirmed in other trauma settings.
Conclusions
Upon ER admission, FIB of major trauma patients shows
strong correlations with rapidly obtainable, routine
laboratory parameters such as Hb and BE. These two
parameters might provide an insightful and rapidly
available tool to identify major trauma patients at risk of
acquired hypofibrinogenemia. Early calculation of ISS
can further increase the ability to predict FIB in these
patients. We propose that FIB can be estimated during
the initial phase of trauma care based on bedside tests.
Key messages
• Plasma fibrinogen of major trauma patients shows
strong correlation with rapidly obtainable, routine
Figure 6 Percentage of patients with adequate, low and critical FIB stratified according to ISS and Hb. Observed percentage of patients
with adequate plasma fibrinogen concentration (FIB) (≥200 mg/dL, green), low FIB (199 to 150 mg/dL, yellow) and critical FIB (<150 mg/dL, red)
when combining the admission variables Injury Severity Score (ISS) and hemoglobin (Hb, g/dL).
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laboratory parameters such as hemoglobin and base
excess, upon admission to the emergency room.
• Based on clinical data, these two parameters might pro-
vide an insightful and rapidly available tool to identify major
trauma patients at risk of acquired hypofibrinogenemia.
• Early calculation of Injury Severity Score can further
increase the ability to predict plasma fibrinogen in these
patients.
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